1. Big Red license.
2. Significant number of placebo patients dropped out of Z160 trials, prospects for eary trial victory(ies).
3. Exalgo sales satisfy cash demands.
4. Novartis pushing an oncology candidate forward.
5. Z944 news.
6. Napodano magic juice?
Garrett said a coordinator at a Texas clinic had a patient on placebo drop out due to pain. I extrapolated on this possibility considering the enrollment criteria was pretty good in terms of selecting patients with real chronic pain.
Cob: The possibility of a buyout is very remote. Read the bylaws and you'll understand why. If a buy out was to happen, which is possible but not likely, we would have been screwed big time. A buy out is the last thing in the world I would want. This puppy is the real deal. To take chump change profits on Zalicus would be foolish. IMHO
Jim Long and calm